Our news

17.03.2020

NeoPhore appoints Dr Matthew Baker as Chief Executive Officer

17 March 2020, Cambridge, UK – NeoPhore Limited, a small molecule cancer immuno-oncology company, today announces the appointment of Dr Matthew Baker a…

08.07.2019

NeoPhore appoints Dr Matthew Baker as VP Immunology

08 July 2019, Cambridge, UK – NeoPhore Limited, a small molecule cancer immuno-oncology company, today announces the appointment of Dr Matthew Baker a…

17.05.2019

Neophore's SAB member publishes article on JCO Precision Oncology

Dr. Luis Diaz, Neophore’s Scientific Advisory Member and Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Hospital has r…

20.03.2019

NeoPhore appoints Dr John Haurum as Non-Executive Director

Former F-star CEO joins the Board of Directors. NeoPhore Limited, a cancer immuno-oncology company, today announces the appointment of Dr John…

Other news

06.08.2019

BioCentury's Emerging Company Profile

CEO Jeff Roix spoke to BioCentury about how NeoPhore Ltd is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of…

08.02.2018

NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology

Scrip Emerging company profile: UK-based NeoPhore, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company…